ImmunoBrain Checkpoint (IBC) is a clinical stage biopharmaceutical company transforming the fight against neurodegeneration and aging by targeting the immune system, restoring brain immune communications and boosting natural repair mechanisms. IBC’s lead program is a proprietary antibody targeting the inhibitory immune checkpoint pathway PD-1/PD-L1, to treat Alzheimer's disease. IBC's novel approach for the treatment of neurodegeneration is based on years of innovative, cutting-edge scientific discoveries made in the lab of Prof. Michal Schwartz at the Weizmann Institute of Science.